Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:BLUENASDAQ:PEPGNASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.50-8.0%$0.56$0.40▼$1.17$10.47M2.2483,613 shs182,761 shsBLUEbluebird bio$4.97$4.53$3.20▼$28.60$48.67M0.27438,555 shsN/APEPGPepGen$1.43-2.7%$1.44$0.88▼$19.30$46.79M1.3832,060 shs57,606 shsRNXTRenovoRx$1.30-4.4%$1.11$0.75▼$1.69$47.54M1.3294,696 shs139,133 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-8.03%-23.53%-4.73%-3.28%-40.70%BLUEbluebird bio0.00%0.00%-0.20%+32.53%-74.87%PEPGPepGen-2.72%-4.67%+3.62%-40.17%-91.93%RNXTRenovoRx-4.41%-6.47%+23.81%+31.87%+11.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos1.3585 of 5 stars0.04.00.00.03.80.80.6BLUEbluebird bio3.3797 of 5 stars3.15.00.00.03.01.71.3PEPGPepGen2.7182 of 5 stars3.23.00.00.01.72.51.3RNXTRenovoRx2.9553 of 5 stars3.55.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ABLUEbluebird bio 2.25Hold$44.60797.38% UpsidePEPGPepGen 2.33Hold$7.67436.13% UpsideRNXTRenovoRx 3.00Buy$7.25457.69% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, PEPG, RNXT, and BLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $11.505/29/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/19/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/9/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.004/28/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.004/4/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/27/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$106.21K98.53N/AN/A$5.23 per share0.10BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/ARNXTRenovoRx$240K198.10N/AN/A($0.28) per share-4.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$13.77M-$1.29N/A∞N/AN/A-75.16%-50.22%8/4/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)PEPGPepGen-$78.63M-$3.13N/AN/AN/AN/A-60.17%-48.88%8/6/2025 (Estimated)RNXTRenovoRx-$10.23M-$0.40N/AN/AN/AN/A-205.96%-110.01%8/12/2025 (Estimated)Latest AIMD, PEPG, RNXT, and BLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.23 million$0.20 million5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/8/2025Q1 2025PEPGPepGen-$0.72-$0.92-$0.20-$0.92N/AN/A3/31/2025Q4 2024RNXTRenovoRx-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.501.371.33BLUEbluebird bio0.370.510.33PEPGPepGenN/A8.478.47RNXTRenovoRxN/A5.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABLUEbluebird bio87.43%PEPGPepGen58.01%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%BLUEbluebird bio1.40%PEPGPepGen5.20%RNXTRenovoRx9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million12.62 millionNot OptionableBLUEbluebird bio5209.79 million9.59 millionOptionablePEPGPepGen3032.72 million31.10 millionNot OptionableRNXTRenovoRx636.57 million22.30 millionNot OptionableAIMD, PEPG, RNXT, and BLUE HeadlinesRecent News About These CompaniesInsider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of StockJune 10, 2025 | insidertrades.comInsider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires 21,000 Shares of StockJune 9, 2025 | marketbeat.comRenovoRx (NASDAQ:RNXT) Raised to "Sell" at Wall Street ZenJune 9, 2025 | americanbankingnews.comAscendiant Capital Markets Forecasts Strong Price Appreciation for RenovoRx (NASDAQ:RNXT) StockJune 7, 2025 | americanbankingnews.comRenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street ZenJune 7, 2025 | marketbeat.comRenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 ResultsJune 6, 2025 | finance.yahoo.comRenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital MarketsJune 5, 2025 | marketbeat.comAscendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€June 5, 2025 | fr.investing.comEarnings call transcript: RenovoRx Q1 2025 revenue exceeds expectationsMay 17, 2025 | investing.comRenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comRenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...May 16, 2025 | finance.yahoo.comLe BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisionsMay 15, 2025 | fr.investing.comTranscription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentesMay 15, 2025 | fr.investing.comRenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comRenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comRenovoRx Reports First Quarter 2025 Financial Results and Business HighlightsMay 15, 2025 | businesswire.comEarnings Preview For RenovoRxMay 14, 2025 | benzinga.comRenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21stMay 14, 2025 | finance.yahoo.comU.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy PlatformMay 6, 2025 | finance.yahoo.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRxApril 30, 2025 | zonebourse.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-PacApril 29, 2025 | zonebourse.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, PEPG, RNXT, and BLUE Company DescriptionsAinos NASDAQ:AIMD$0.50 -0.04 (-8.03%) As of 06/13/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.PepGen NASDAQ:PEPG$1.43 -0.04 (-2.72%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.42 0.00 (-0.35%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.RenovoRx NASDAQ:RNXT$1.30 -0.06 (-4.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.29 -0.01 (-0.77%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
